Better Therapeutics (Better Therapeutics) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics 3-Year Revenue Growth Rate?

Better Therapeutics's Revenue per Share for the three months ended in Sep. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Better Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Better Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Better Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Better Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Better Therapeutics's 3-Year Revenue Growth Rate falls into.

Better Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Better Therapeutics (OTCPK:BTTX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Better Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Better Therapeutics (Better Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

548 Market Street, Suite 49404, San Francisco, CA, USA, 94104

Website

https://www.bettertx.com

Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.

Executives

Elder Granger	director	5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman	officer: Chief Medical Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe	director, officer: See Remarks	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry	director, 10 percent owner, officer: See Remarks	1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino	director	C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust	10 percent owner	C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen	officer: See Remarks	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum	director, 10 percent owner, officer: Chief Executive Officer	4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu	director	311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski	officer: Chief Commercial Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds	officer: Chief Product Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona	director	1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust	10 percent owner	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104